Sarah Aebersold Sells 2,695 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 2,695 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80. Following the sale, the insider now directly owns 43,165 shares of the company's stock, valued at approximately $1,098,117.60. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Trading Down 0.3 %

BLFS traded down $0.07 during trading on Friday, reaching $24.99. 569,608 shares of the company's stock were exchanged, compared to its average volume of 350,123. The company's fifty day moving average price is $26.40 and its 200-day moving average price is $25.48. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The firm has a market capitalization of $1.17 billion, a PE ratio of -23.58 and a beta of 2.04.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. During the same period last year, the firm posted ($0.21) earnings per share. As a group, equities analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analysts Set New Price Targets

BLFS has been the subject of a number of research reports. Northland Securities raised their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. StockNews.com raised shares of BioLife Solutions from a "sell" rating to a "hold" rating in a report on Wednesday. KeyCorp raised their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Friday, December 13th. Benchmark reissued a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, HC Wainwright raised their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $29.86.

Institutional Trading of BioLife Solutions

Large investors have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of BioLife Solutions in the 4th quarter valued at $26,000. Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions in the 4th quarter valued at $31,000. Quest Partners LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter valued at $57,000. Finally, 1620 Investment Advisors Inc. increased its holdings in BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 675 shares in the last quarter. Institutional investors own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.